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Objectives: The role of surgical resection for brain metastases from non–small cell
lung cancer is evolving. Although resection of primary lung cancer and metachro-
nous brain metastases is superior to other treatment modalities in prolonging sur-
vival and disease-free interval, resection of the primary non–small cell lung cancer
and synchronous brain metastases is controversial.
Methods: From January 1975 to December 1997, 220 patients underwent surgical
treatment for brain metastases from non–small cell lung cancer at our institution.
Twenty-eight (12.7%) of these patients underwent surgical resection of synchro-
nous brain metastases and the primary non–small cell lung cancer.
Results: The group comprised 18 men and 10 women. Median age was 57 years
(range 35-71 years). Twenty-two (78.6%) patients had neurologic symptoms.
Craniotomy was performed first in all 28 patients. Median time between cranioto-
my and thoracotomy was 14 days (range 4-840 days). Pneumonectomy was per-
formed in 4 patients, bilobectomy in 4, lobectomy in 18, and wedge excision in 2.
Postoperative complications developed in 6 (21.4%) patients. Cell type was adeno-
carcinoma in 11 patients, squamous cell carcinoma in 9, and large cell carcinoma in
8. After pulmonary resection, 17 patients had no evidence of lymph node metastases
(N0), 5 had hilar metastases (N1), and 6 had mediastinal metastases (N2). Twenty-
four (85.7%) patients received postoperative adjuvant therapy. Follow-up was com-
plete in all patients for a median of 24 months (range 2-104 months). Median sur-
vival was 24 months (range 2-104). Survival at 1, 2, and 5 years was 64.3%, 54.0%,
and 21.4%, respectively. The presence of thoracic lymph node metastases (N1 or
N2) significantly affected 5-year survival (P = .001).
Conclusion: Although the overall survival for patients who have brain metastases
from non–small cell lung cancer is poor, surgical resection may prove beneficial in
a select group of patients with synchronous brain metastases and lung cancer with-
out lymph node metastases.
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Lung cancer is the leading cause of cancerdeath in both men and women in the UnitedStates.1 The incidence of brain metastasesfrom lung cancer is approximately 40% to60% in autopsy series.2,3 Clinically, brainmetastasis is diagnosed in 25% to 30% of
patients with non–small cell lung cancer (NSCLC) during
the course of their disease.4,5 Surgical resection of these
metastatic lesions is considered in only 25% of patients.6
Several studies have reported long-term survival with surgi-
cal treatment of metachronous brain metastases in patients
with primary NSCLC.7,8 However, the results of surgical
treatment of synchronous brain metastases along with the
primary tumor is controversial. This review retrospectively
examines our experience in patients who underwent resec-
tion of synchronous brain metastases and of the primary
NSCLC and analyzes prognostic factors affecting survival.
Patients and Methods
From January 1975 to December 1997, 220 patients underwent
surgical resection of brain metastases resulting from NSCLC at our
institution. Twenty-eight (12.7%) of these patients underwent sur-
gical resection of synchronous brain metastases along with the pri-
mary NSCLC. The medical records of these 28 patients were
reviewed after we obtained institutional review board approval.
The medical record of each patient was examined for age, sex, his-
tologic type and grade, postoperative thoracic tumor stage, surgi-
cal procedure, postoperative complications, adjuvant therapy, and
survival. Follow-up was obtained by outpatient visits and corre-
spondence with primary physicians. Cerebral and pulmonary
resection was considered curative if all gross evidence of disease
was removed. In all patients, postoperative staging was done
according to the 1997 International Staging System for Non–Small
Cell Lung Cancer.9 Operative mortality included patients who died
within the first 30 days after the thoracic procedure and those who
died later but during the same hospitalization. Survival was esti-
mated by the Kaplan-Meier method with the date of diagnosis used
as the starting point and the date of death or last follow-up as the
end point.10 The influence of variables on survival was analyzed by
the log-rank test for multivariate analyses.11,12
Clinical Findings
The group comprised 18 men and 10 women. Median age was 57
years with a range of 35 to 71 years. Twenty-two (78.6%) patients
had neurologic symptoms including headache in 9, ataxia in 7,
seizure in 4, dizziness in 4, weakness in 3, vomiting in 2, and
blurred vision and confusion in 1 each. Six patients had pulmonary
symptoms, including chest pain in 2, hemoptysis in 2, and short-
ness of breath in 1. In 4 of the 28 patients, the location of the pri-
mary tumor was unknown at the time of initial presentation.
Median time to the discovery of the primary tumor in these patients
was 4 months with a range of 2 to 12 months. Preoperative workup
included computed tomographic (CT) scanning of the chest and
upper part of the abdomen, magnetic resonance imaging or CT
scan of the brain, and bone scan.
Craniotomy preceded pulmonary resection in all 28 patients. A
solitary brain metastasis was removed in 26 (92.9%) patients. Two
patients had removal of 2 adjacent lesions in a single specimen.
Cerebral resection was complete in all 28 patients. Median time
between craniotomy and thoracotomy was 14 days with a range of
4 to 840 days. Pulmonary resection included pneumonectomy in 4
(14.3%) patients, bilobectomy in 4 (14.3%), lobectomy in 18
(64.3%), and wedge excision in 2 (7.1%). Wedge excisions were
performed because of poor pulmonary reserve. Complete pul-
monary resection and lymph node dissection was performed in all
28 patients. No patient had preoperative mediastinoscopy.
The tumor was adenocarcinoma in 11 (39.2%) patients, squa-
mous cell carcinoma in 9 (32.1%), and large cell carcinoma in 8
(28.6%). The tumor was grade 2 in 1 patient, grade 3 in 6, and
grade 4 in 21 patients. Lymph node metastases were present in 11
(39.3%) patients and were N1 in 5 (17.9%) and N2 in 6 (21.4%).
For the lung tumor alone, the postoperative stage was stage IA or
IB in 15 (53.6%) patients, stage IIA or IIB in 6 (21.4%), and stage
IIIA in 7 (25.0%).
No patient received preoperative radiation or chemotherapy.
Postoperative adjuvant therapy was given in 24 (85.7%) patients:
whole brain radiation (WBR) alone in 15 (53.6%); WBR with sys-
temic chemotherapy in 6 (21.4%); and WBR, systemic chemother-
apy, and thoracic radiation in 3 (7.1%). The median dose of WBR
was 35 Gy with a range of 25 to 40 Gy. Patients were selected to
receive adjuvant therapy at the discretion of the surgeon and con-
sulting oncologist or radiation therapist.
Results
There were no operative deaths after pulmonary resection.
Complications occurred in 6 (21.4%) patients after the tho-
racic procedure and in 1 (3.6%) patient after the neurosurgi-
cal procedure. Vocal cord paralysis, empyema, pneumonia,
atrial fibrillation, prolonged air leak, and postoperative
bleeding necessitating reoperation occurred in 1 patient
each after pulmonary resection. Only 1 patient had a com-
plication, pseudomembranous colitis, after the neurosurgi-
cal procedure.
Follow-up was complete in all 28 patients for a median
follow-up of 24 months and a range of 2 to 104 months.
Recurrence developed in 18 (64.3%) patients and was local
(5 lung, 3 brain) in 8 (44.4%), distant (2 bone, 2 adrenal, 1
adrenal/liver) in 5 (27.8%), and both local and distant (3
brain/lung, 1 brain/liver, 1 bone/liver) in 5 (27.8%). Four of
the 7 (57.1%) patients who had cerebral recurrence did not
receive adjuvant WBR. Three patients underwent late reop-
eration for recurrent brain metastases, 4 patients received
thoracic radiation therapy, and 2 received chemotherapy for
late distant recurrence. Currently, 4 patients are alive with-
out evidence of recurrent disease at 10, 12, 39, and 49
months after pulmonary resection. The cause of death in the
remainder was recurrent lung cancer in 18 (64.3%), unrelat-
ed to their cancer in 4 (14.3%), and unknown in 2 (7.1%).
Median survival was 24 months and ranged from 2 to
550 The Journal of Thoracic and Cardiovascular Surgery • September 2001
ED
ITO
RIA
L
CH
D
G
TS
A
CD
G
TS
CSP
TX
General Thoracic Surgery Billing et al
104 months. The overall survival at 1, 2, and 5 years was
64.3% (95% confidence intervals [CI], 48.8%-84.7%),
54.0% (95% CI, 37.9%-75.6%), and 21.4% (95% CI,
10.5%-43.6%), respectively (Figure 1). Lymph node metas-
tases (N1 and N2) had a statistically significant impact on
survival (P = .001). No patient with lymph node metastases
survived longer than 3 years after resection (Figure 2). WBR
affected survival, as median survival for patients who
received WBR was 20.5 months compared with 4 months in
patients who did not receive adjuvant WBR (P = .18).
However, this difference was not significant. Adjuvant
chemotherapy or thoracic radiation did not affect long-term
survival.
Univariate analysis revealed that lymph node metastases
and postoperative thoracic stage significantly affected sur-
vival. Multivariate analysis found that only lymph node
metastases significantly affected 5-year survival. Age, sex,
tumor histologic type or grade, primary tumor location, time
interval between surgical procedures, type of resection, and
adjuvant therapy did not significantly affect survival.
Comments
The development of brain metastases is usually a fatal event
in the natural history of NSCLC. The median survival from
the time of diagnosis of brain metastases to the time of death
is approximately 1 to 2 months without treatment.13
Corticosteroid administration in patients with brain metas-
tases results in dramatic and rapid improvement in neuro-
logic symptoms. However, corticosteroids do not prolong
survival beyond 3 months.14 WBR alone has early favorable
results, with reduction of neurologic symptoms in more than
75% of patients. However, this benefit is short-lived, with a
median survival of only 3 to 6 months.15,16 In addition, the
risk of dementia with high-dose WBR is significant.
Surgical resection of brain metastases from NSCLC has
been performed for more than 70 years.17 Early surgical
resection of cerebral metastases was considered ineffective
with rare long-term survivors because of inadequate neu-
roanesthesia techniques and perioperative care resulting in
high morbidity and mortality.18 With improved neurosurgi-
cal techniques and perioperative care, morbidity and mor-
tality rates have decreased significantly. Resection of soli-
tary brain metastasis has become standard treatment with
low morbidity and an operative mortality of 0% to 3%.19-21
There were no operative deaths in our report.
With these improved surgical outcomes, controversy
developed as to which modality (surgery vs radiation thera-
py) should be used to treat patients with brain metastases
from NSCLC. Two retrospective reviews compared WBR
alone versus WBR plus surgical resection in patients with
solitary NSCLC brain metastasis.22,23 Both studies demon-
strated a significant survival advantage of surgery plus
WBR versus WBR alone. The median survivals of patients
undergoing surgery and WBR was 16 to 19 months and only
4 to 6 months in patients receiving WBR alone. Two
prospective studies randomized surgical resection plus
WBR to WBR alone with similar results.24,25 In addition,
Patchell and colleagues24 demonstrated that patients under-
going the combined approach also had significantly less
recurrence at the original site of metastasis, as well as
improved quality of life. The survival advantage of com-
bined therapy found in the above reports was not evident in
our report, but the trend was toward improved survival.
An alternative approach to cerebral resection is cerebral
stereotactic radiosurgery (RS). RS delivers a single fraction
of radiation to a specific intracranial target, thus minimizing
exposure to the normal surrounding parenchyma.
Retrospective studies of RS plus WBR for the treatment of
brain metastases have demonstrated median survivals of 6 to
11 months.26,27 Controversy exists whether WBR is of ben-
efit when combined with RS. One nonrandomized study
demonstrated that if WBR was not added to RS, local recur-
Figure 1. Probability of survival (death from any cause) of 28
patients who underwent resection of synchronous brain metas-
tases and primary lung cancer. Zero time on the abscissa repre-
sents the date of diagnosis.
Figure 2. Probability of survival (death from any cause) of 28
patients who underwent resection of synchronous brain metas-
tases and primary lung cancer, stratified by lymph node involve-
ment. Zero time on the abscissa represents the date of diagnosis.
Survival decreased with lymph node involvement (P = .001).
Billing et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 3   551
TX
G
TS
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
rence rates were higher but survival was not affected.28 In
contrast, a similar study demonstrated that WBR was of no
benefit when combined with RS.29 One retrospective report
by Mehta and coworkers30 analyzed patients who received
WBR in combination with RS. In this study, the investiga-
tors observed a median survival of 13 months and improved
functional independence and local control. These results
were similar to those observed with surgical resection, sug-
gesting that RS plus WBR is a reasonable alternative for
patients with solitary brain metastasis or for patients with
multiple metastases or surgically inaccessible lesions.
Whether RS will be superior to surgical resection will
require randomized prospective studies.
Patients in whom metachronous brain metastases devel-
op from NSCLC have significantly improved survival after
successful surgical resection with 5-year survivals of 21% to
45%.19,20,31 Several factors have been found to influence
survival, including complete resection, stage of tumor,
locoregional disease, and prolonged interval between thora-
cotomy and craniotomy. Several reports have shown signif-
icantly worst survival with synchronous lesions.32-34
Surgical resection alone for synchronous lesions resulted in
5-year survivals of only 5% to 10% with a median survival
of less than 10 months.32 Surgical resection of the primary
lung tumor has been suggested to improve survival after
craniotomy. Recently, Andrews, Gluck, and Konchingeri33
demonstrated a median survival of 25.7 months in patients
who underwent resection of the primary NSCLC compared
with 9.1 months in patients who did not undergo resection
of the primary tumor. Other reports of combined therapy
also suggested improvement in survival, but the number of
cases in each study was small.35,36 Our report represents one
of the largest series on the effectiveness of combined treat-
ment of the primary tumor and synchronous brain lesions.
The most important determinant of survival in this report
was the presence of lymph node metastases. Five-year sur-
vival of patients with N0 disease was 35%. No patient who
had nodal involvement survived longer than 3 years after
resection of the primary tumor. This is in contrast to the
observations of Burt and associates,37 who found no differ-
ence in survival between patients with stage I and II NSCLC
versus patients with stage III and IV disease. However, they
did demonstrate that patients who underwent complete
resection had a significantly prolonged survival of 21
months versus 10 months for those who did not have resec-
tion or who had incomplete resection. All 28 of our patients
had complete resection of their primary NSCLC.
This series represents a very select group of patients who
underwent combined resection of stage IV NSCLC. Patients
who have symptomatic synchronous brain lesions should
undergo craniotomy first to prevent neurologic complica-
tions. Subsequent resection of the primary tumor should be
performed only if there is no evidence of mediastinal lymph
node involvement with mediastinoscopy. Complete resec-
tion of all disease should be performed. Operative mortality
and morbidity for this combined approach is low. The
majority of patients should receive adjuvant WBR.
In conclusion, resection of solitary synchronous brain
metastases and the primary tumor should be performed only
in a select group of patients with NSCLC. Preoperative evi-
dence of mediastinal lymph node metastases should pre-
clude resection of the primary tumor because long-term sur-
vival in those patients is poor.
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Discussion
Dr Joseph I. Miller, Jr (Atlanta, Ga). This topic presents a
significant problem to thoracic surgeons, neurosurgeons, and
oncologists alike. The authors have reported the second largest
group of patients with synchronous brain metastasis, 28 of 220
patients, or 12.7% of their group during a 22-year period. The
largest group reported was by Dr Michael Burt and his colleagues
at Memorial before this society in 1991. At that time they reported
on 65 patients, or 35% of their group, with synchronous brain
metastasis during a 16-year period. Dr Magilligan from Detroit in
1988 reported on 14 patients with synchronous brain metastasis. 
For metachronous single brain metastasis developing after
resection of a primary lung cancer and in the absence of other
metastatic disease, surgical resection of the cranial lesion followed
by WBR is the treatment of choice. Therefore, my remarks will be
confined to the subset of patients as addressed in this presentation. 
The authors have correctly pointed out that the majority of
General Thoracic Surgery Billing et al
these patients have neurologic symptoms and that craniotomy
should be performed before thoracic resection. Twenty-four of
their 28 patients received WBR at dosages from 2500 to 4000 Gy.
Recurrent carcinoma developed in 18, and at present only 4 of the
28 are alive, at follow-ups ranging from 10 to 31 months. Seven
had recurrence in the brain, of whom 4 had not received WBR. As
reported by Dr Miller, the 1-year, 2-year, and 5-year survivals were
64%, 54%, and 21%, respectively. 
No patient in the group with lymph node metastasis survived
more than 3 years. The authors concluded that lymph node metas-
tasis and WBR significantly influence survival. This is in con-
tradistinction to findings of the Memorial group, who reported that
surgical stage had no influence on long-term survival. This is also
in contradistinction to the report of Magilligan in 1988 from Henry
Ford Hospital, which showed no difference in long-term survival
regardless of stage when a complete resection had been carried out.
Magilligan’s series was the third largest and received the Maxwell
Chamberlain award at that time. 
The authors point out that cerebrotactic RS may be an alterna-
tive to open craniotomy. Regardless, it appears that both groups
benefit from WBR.
My own experience is limited to only 6 patients in the past 25
years with synchronous brain metastasis. Three of them had recur-
rent disease at 6 to 18 months, all intracranially, and 3 are alive at
1 year, 5 years, and more than 10 years, respectively. All patients
received WBR. 
I would like to ask the authors the following questions: First,
how do you explain the discrepancy between the effect of patho-
logic stage of the lung cancer on survival in your study and the
other 2 large reported series of Burt and Magilligan? Second, in
your conclusions, you state that no patient with N1 or N2 disease
determined preoperatively, excluding a positive mediastinoscopic
result, should undergo resection. I think most surgeons might dis-
agree with that. Third, which patients should undergo open cranial
resection and which craniotactic RS? Does the decision depend on
the surgeon’s bias, and how does craniotactic RS affect outcome?
Fourth, what is the current neurosurgical approach at the Mayo
Clinic? Is it open or is it stereotactic surgery? Is WBR now given
to all patients? 
Dr Miller. Thank you, Dr Miller, for your comments and
review of this paper. 
To address your first question in regard to pathologic stage, you
are correct that both Dr Burt’s and Dr Magilligan’s work demon-
strated no significant survival change in regard to stage. There was
a distinction in Dr Burt’s paper in regard to complete and incom-
plete resection. We believe that with a larger patient population,
ideally up to the numbers that Dr Burt generated at the Sloan-
Kettering Cancer Center, stage might not prove to be significant.. 
As you recognized, only 11 patients in this population had
stage II or stage III disease. We believe that complete resection of
all gross disease neurosurgically and thoracically is the most
important survival component. 
In regard to our neurosurgical colleagues at the Mayo Clinic,
they currently recommend open resection for patients who have a
solitary brain metastasis from NSCLC. However, they are in the
investigational stage of using RS. Furthermore, our colleagues at
the Mayo Clinic published an article in the Journal of
Neurosurgery in 1992, in which the use of WBR was discussed.
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Dr Thomas W. Rice (Cleveland, Ohio). I would like to make a
comment and ask 2 questions. We know that the prognosis for
stage IIIA and IIIB lung cancer is dismal. Why should a metasta-
sis to the brain make this more of a surgical disease? I always find
that somewhat paradoxical. 
The first question concerns the use of mediastinoscopy in the
present group. Did you use mediastinoscopy routinely? From your
other responses I would expect that you would now do medi-
astinoscopy in all these patients. Second, 72% of your patients had
local recurrence, and I notice that you did not give any local ther-
apy. What would your comments be on the management of a
patient now when you perform resection regardless of the lymph
node finding? Would you use radiation in the patients who other-
wise have stage I and stage II disease?
Dr Miller. To answer your second question first, as Dr Miller
mentioned, 4 of the 7 patients who had local recurrence within the
brain did not undergo WBR; therefore, we would recommend
WBR for all patients who underwent metastasectomy. 
In regard to the chest, at the discretion of the oncologists and
thoracic surgeons at that time, some of those patients did undergo
systemic therapy afterward, but the decision was not based on
nodal status. 
In regard to mediastinoscopy, Dr Pairolero and Dr Trastek did
the majority of these earlier cases, and mediastinoscopy was not
performed routinely, but that policy has changed. 
Dr Thomas M. Egan (Chapel Hill, NC). What will you do next
week when you do a positron emission tomographic scan on one
of these patients after the craniotomy and identify N1 disease? Will
you operate or not? 
Dr Miller. We do not have a positron emission tomographic
scanner at the Mayo Clinic. If I had a patient with N1 disease at the
present time, I would not recommend resection. I would recom-
mend systemic chemotherapy and WBR. 
Dr Thomas R. J. Todd. If I read your abstract correctly, this
was a group of 28 patients out of 220 that came with synchronous
brain and chest malignancy. What was different about those 28 that
brought them to surgery? 
Dr Miller. This was a select group that had only isolated cere-
bral metastasis. 
Currently all patients at the Mayo Clinic who undergo metastasec-
tomy for NSCLC receive WBR. 
Dr Mark J. Krasna (Baltimore, Md). I would like to discuss
a paper presented by one of our group before the Southern
Thoracic Surgical Association in 1997. The paper concerned 47
patients with synchronous metastasis and NSCLC. I bring it up
because, in that group, we also found that there were no long-
term survivors at 5 years with the N2 subgroup of patients; if the
patients had N0 disease, the 5-year survival was 39%. I would
reiterate all of your comments regarding the importance of
lymph node staging. 
I do have 2 questions similar to those asked earlier. We have
used the Gamma Knife in lieu of craniotomy in our last 12 patients.
What has changed, though, in our institution is that we are now
accepting more than one metastasis. We are doing oligometasta-
sectomies, if you will, by using 3 or 4 Gamma Knife lesions for
brain metastases, not just solitary metastases. Is that being done as
well at Mayo or are you just treating solitary brain metastases?
Last, what would you do if you had a patient with no evidence of
lymph node metastasis on CT scan but a solitary brain metastasis?
Would you at the Mayo Clinic perform a mediastinoscopy now
routinely before doing this operation? 
Dr Thomas R. J. Todd (Toronto, Ontario, Canada). Mark,
before he answers your question, I have a question for you. In your
paper that was presented before the Southern Thoracic Surgical
Association, do you recall within that group of 47 patients the
number who had N2 disease? 
Dr Krasna. It was at least half. I do not recall the exact number.
Dr Miller. At the Mayo Clinic, a patient who had a solitary
brain metastasis would be treated by neurosurgical resection and
then by mediastinoscopy after the recovery period. If the patient
had evidence of mediastinal lymphadenopathy, we would not pro-
ceed with surgical resection for malignancy. That is why I con-
cluded in our summary that in the future these patients may war-
rant systemic chemotherapy and thoracic radiation directed at the
primary tumor, which may enable them to undergo surgical resec-
tion later. As you can see, this is very small number of patients, 28
patients over 27 years, so it would be very difficult to conduct a
prospective study.
